Gene · 2249
Papers3,660
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
1,181 to 1,200 of 3,660
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Residual molecular and behavioral effects of the phenylpyrazole pesticide fipronil in larval zebrafish (Danio rerio) following a pulse embryonic exposure. | Comp Biochem Physiol Part D Genomics Proteomics | 2020 | 32977147 | PubTator, text mining | PubMed |
| Tumor Endothelial Cells (TECs) as Potential Immune Directors of the Tumor Microenvironment - New Findings and Future Perspectives. | Front Cell Dev Biol | 2020 | 32974337 | PubTator, text mining | PubMed |
| Genetic Engineering as a Strategy to Improve the Therapeutic Efficacy of Mesenchymal Stem/Stromal Cells in Regenerative Medicine. | Front Cell Dev Biol | 2020 | 32974331 | PubTator, text mining | PubMed |
| [Chinese Expert Consensus on Next Generation Sequencing Diagnosis for Non-small Cell Lung Cancer (2020 Edition)]. | Zhongguo Fei Ai Za Zhi | 2020 | 32957170 | PubTator, text mining | PubMed |
| Multi-layered Spatial Transcriptomics Identify Secretory Factors Promoting Human Hematopoietic Stem Cell Development. | Cell Stem Cell | 2020 | 32946788 | PubTator, text mining | PubMed |
| Revisiting 3D chromatin architecture in cancer development and progression. | Nucleic Acids Res | 2020 | 32941624 | PubTator, text mining | PubMed |
| In Vitro Innovation of Tendon Tissue Engineering Strategies. | Int J Mol Sci | 2020 | 32937830 | PubTator, text mining | PubMed |
| Sequencing for an interdisciplinary molecular tumor board in patients with advanced breast cancer: experiences from a case series. | Oncotarget | 2020 | 32934773 | PubTator, text mining | PubMed |
| Mesenchymal Stem Cells as a Promising Cell Source for Integration in Novel In Vitro Models. | Biomolecules | 2020 | 32927777 | PubTator, text mining | PubMed |
| Next-Generation Sequencing of Advanced GI Tumors Reveals Individual Treatment Options. | JCO Precis Oncol | 2020 | 32923905 | PubTator, text mining | PubMed |
| Vulvar Squamous Cell Carcinoma: Comprehensive Genomic Profiling of HPV+ Versus HPV- Forms Reveals Distinct Sets of Potentially Actionable Molecular Targets. | JCO Precis Oncol | 2020 | 32923875 | PubTator, text mining | PubMed |
| MicroRNA regulation of murine trophoblast stem cell self-renewal and differentiation. | Life Sci Alliance | 2020 | 32907860 | PubTator, text mining | PubMed |
| Personalized cancer therapy prioritization based on driver alteration co-occurrence patterns. | Genome Med | 2020 | 32907621 | PubTator, text mining | PubMed |
| VDR-SOX2 signaling promotes colorectal cancer stemness and malignancy in an acidic microenvironment. | Signal Transduct Target Ther | 2020 | 32900990 | PubTator, text mining | PubMed |
| An Amyotrophic Lateral Sclerosis-Associated Mutant of C21ORF2 Is Stabilized by NEK1-Mediated Hyperphosphorylation and the Inability to Bind FBXO3. | iScience | 2020 | 32891887 | PubTator, text mining | PubMed |
| Peptides to combat viral infectious diseases. | Peptides | 2020 | 32889022 | PubTator, text mining | PubMed |
| Paired tumor sequencing and germline testing in breast cancer management: An experience of a single academic center. | Cancer Rep (Hoboken) | 2020 | 32881420 | PubTator, text mining | PubMed |
| FGF/FGFR signaling in health and disease. | Signal Transduct Target Ther | 2020 | 32879300 | PubTator, text mining | PubMed |
| Response to Abemaciclib After 10 Lines of Therapy Including Palbociclib in Metastatic Breast Cancer: A Case Report With Literature Review. | Oncol Ther | 2020 | 32876928 | PubTator, text mining | PubMed |
| Influence of Conditioned Media on the Re-Differentiation Capacity of Human Chondrocytes in 3D Spheroid Cultures. | J Clin Med | 2020 | 32872610 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/2249/papers?page=60